MyOme and SickKids Collaborate to Clinically Validate DNA Methylation Signatures Using Long-Read Sequencing

Markets PR Newswire By PR Newswire 04 Nov 2026 17:00 1 min read
MyOme and SickKids Collaborate to Clinically Validate DNA Methylation Signatures Using Long-Read Sequencing

MyOme Licenses SickKids-Developed DNA Methylation Signatures to Strengthen Long-Read Rare Disease Testing. MENLO PARK, Calif., Nov. 4, 2026 /PRNewswire/ -- MyOme, a CLIA-certified, CAP-accredited clinical whole-genome analysis company, today announced a licensing and research agreement...

Covered in this story

Call it yourself

No calls on $DNA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.

Make the first call on Ginkgo Bioworks Holdings Inc Class →
Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.